BioCryst Pharmaceuticals | BCRX - 销售和管理费用

股票价格

9.38

每天变化

-0.18 -1.88%

每月一次

0.86%

每年

33.24%

Q2 预测

9.30

金融业

USD

USD 514.16M

现金及等价物

USD 335.91M

USD 9.52M

USD 404.35M

USD 196.07M

USD 828.6M

股息收益率

0

USD 260.39M

USD 51.7M

536

EPS每股收益

USD 1.17

股本和储备

USD -119.15M

USD 153.05M

债务利息支出

USD 14.14M

USD -0.13

USD 428.67M

USD 1.96B

USD 245.85M

USD 146.17M

USD 260.39M

普通股股本

USD 213.06M

6.06

USD 248.02M

USD 406.56M

销售和管理费用

USD 95.78M

USD 5.4M

贸易债权人

USD 15.83M

应收帐款人

USD 106.82M

	销售和管理费用	更改		日
Alnylam Pharmaceuticals	USD 285.06M		22.47M	2025-12
BioCryst Pharmaceuticals	USD 95.78M		12.77M	2025-12
Chugai Pharma	JPY 36.93B		9.04B	2025-12
Daiichi Sankyo	JPY 228.23B		39.15B	2025-12
DBV Technologies	USD 3.63M		3.18M	2025-09
Enanta Pharmaceuticals	USD -1.05		0.31	2024-12
Gilead Sciences	USD 1.78B		425M	2025-12
GlaxoSmithKline	GBP 2.68B		518M	2025-12
Glaxosmithkline	GBP 3.56B		650.29M	2025-12
Incyte	USD 390.41M		61.33M	2025-12
Ionis Pharmaceuticals	USD 130M		43.43M	2025-12
Karyopharm Therapeutics	USD 9.56M		17.63M	2025-12
Neurocrine Biosciences	USD 301.8M		10.2M	2025-12
Novavax	USD 25.53M		1.34M	2025-12
PTC Therapeutics	USD 87.2M		3.15M	2025-12
Regeneron Pharmaceuticals	USD 775M		117.2M	2025-12
Roche Holding	CHF 7.28B		3.99B	2025-12
Sarepta Therapeutics	USD 105.38M		28.27M	2025-12
Ultragenyx Pharmaceutical	USD 89M		2.38M	2025-12
Vertex Pharmaceuticals	USD 487M		41.9M	2025-12